Fibromyalgia: knowns, unknowns, and current treatment
1New York University School of Medicine, Hospital for Joint Diseases, New York, New York 10016, USA. brucesol@verizon.net
Bulletin of the NYU Hospital for Joint Diseases
|October 26, 2010
Summary
Fibromyalgia syndrome (FMS) is a complex chronic pain condition. Recent research highlights central pain processing, genetics, and external factors, leading to new, effective fibromyalgia treatments.
Area of Science:
- Rheumatology
- Neuroscience
- Genetics
Background:
- Fibromyalgia is a chronic condition characterized by widespread musculoskeletal pain, fatigue, cognitive difficulties, and sleep disturbances.
- The exact pathophysiology of fibromyalgia syndrome (FMS) remains incompletely understood, presenting challenges in developing effective treatments.
- Existing knowledge gaps necessitate further investigation into the underlying mechanisms of FMS.
Purpose of the Study:
- To review current understanding of fibromyalgia pathogenesis.
- To discuss emerging concepts in fibromyalgia development.
- To summarize existing and novel therapeutic strategies for fibromyalgia.
Main Methods:
- Literature review of recent studies on fibromyalgia.
- Analysis of accepted and novel theories regarding FMS pathogenesis.
- Evaluation of current and emerging treatment options for fibromyalgia symptoms.
Main Results:
- Central pain processing, genetic predispositions, and environmental factors are implicated in FMS development.
- New therapeutic approaches targeting these factors have shown promise in alleviating fibromyalgia symptoms.
- Understanding the multifactorial nature of FMS is crucial for effective management.
Conclusions:
- Recent advancements offer new insights into fibromyalgia pathophysiology.
- Emerging therapies show potential for improved patient outcomes in fibromyalgia.
- Continued research is vital for refining treatment strategies for this complex syndrome.
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:25Analgesia and Pain Management
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
01:31Skeletal Muscle Relaxants: Therapeutic Uses
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx as...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:20COPD: Pathogenesis and Clinical Features
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...